Aktueller Stand der Chemotherapie gastrointestinaler Tumoren

  • W. Queißer
Conference paper
Part of the Verhandlungen der Deutschen Gesellschaft für Innere Medizin book series (VDGINNERE, volume 94)

Zusammenfassung

Die Chemotherapie gastrointestinaler (GI) Tumoren stellt eines der zentralen Probleme der Krebsmedizin dar. Angenommen, wir fänden ein neues therapeutisches Prinzip, mit dem alle nicht mehr chirurgisch angehbaren Tumoren zur Ausheilung gebracht werden könnten, so würde angesichts der Häufigkeit von GI-Tumoren die allgemeine Krebsheilungsrate schlagartig drastisch verbessert werden können.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Sheridan WP, Medley G, Brodie GN (1985) Non-Hodgkin’s lymphoma of the stomach: A prospective pilot study of surgery plus chemotherapy in eraly and advanced disease. J Clin Oncol 3:495–500PubMedGoogle Scholar
  2. 2.
    Shiu MH, Nisce LZ, Pinna A, Straus DJ, Tome M, Filippa DA, Lee BJ (1986) Recent results of multimodal therapy of gastric lymphoma. Cancer 58:1389–1399PubMedCrossRefGoogle Scholar
  3. 3.
    Rosenberg JC, Lichter AS, Roth JA, Kelsen DP (1985) Cancer of the esophagus. In: de Vita VT, Hellman S, Rosenberg SA, (eds) Cancer. Principles & Practice of Oncology. Lippincott, London Mexico City New York St. Louis Sao Paulo SyndneyGoogle Scholar
  4. 4.
    Kelsen DP, Hilaris B, Coonley C, Chapman R, Lesser M, Dukeman M, Heelan R, Bains M (1983) Cisplatin, vindesine and bleomycin combination chemotherapy of local-regional and advanced esophageal carcinoma. Am J Med 75:645–652PubMedCrossRefGoogle Scholar
  5. 5.
    Kelsen DP, Brains MS, Cvitkovic E, Golbey R (1979) Vindesine in the treatment of esophageal carcinoma: A phase II study. Cancer Treat Rep 63:2019–2021PubMedGoogle Scholar
  6. 6.
    Queißer W, Heim ME (1981) Chemotherapy in alimentary tract malignomas. Hepatogastroenterology 28:276–283PubMedGoogle Scholar
  7. 7.
    Queißer W, Flechtner H (1986) Chemotherapy of advanced gastric carcinoma. Onkologie 9:319–331PubMedCrossRefGoogle Scholar
  8. 8.
    Schnitzler G, Queißer W, Heim ME, König H, Katz R, Fritze D, Herrmann R, Arnold H, Henß H, Trux FA, Bloch R, Keymling M, Wolkewitz KD, Fritsch H, Hanisch I, Brumen L, Edler L (1986) Phase III study of 5-FU and carmustine versus 5-FU, carmustine, and doxorubicin in advanced gastric cancer. Cancer Treat Rep 70:477–479PubMedGoogle Scholar
  9. 9.
    Flechtner H, Queißer W, Heim ME, Henß H, Arnold H, Fritze D, Herrmann R, Fritsch H, Fritz M, Trux FA, Kabelitz K, Edler L (1987) 5-fluorouracil, 4-Epidoxorubicin, and mitomycin C (FEM) combination chemotherapy for advanced gastric carcinoma. A phase-II trial by the „Chemotherapiegruppe gastrointestinaler Tumoren (CGT)“. Onkologie 10:67–71PubMedCrossRefGoogle Scholar
  10. 10.
    Schnitzler G, Queißer W, Meim ME, Hartwich G, König H, Meiser RJ, Pappas A, Trux FA, Witte S, Hanisch I, Katz R, Pretner M, Fritze D (1986) Prospektiv randomisierte Prüfung von 5-Fluorouracil, Adriamycin, BCNU (FAB) versus Beobachtung beim metastasierten Pankreaskarzinom. Tumor Diagnostik und Therapie 7:135–138Google Scholar
  11. 11.
    Herrmann R, Knuth A, Kleeberg U, Middecke R, Abel U, for the Arbeitsgemeinschaft Internistische Onkologie (1986) Randomized multicenter trial of sequential methotrexate (MTX) and 5-fluorouracil (FU) vs FU alone in metastatic colorectal carcinoma (CRC) J Cancer Res Clin Oncol 111 [Suppl]:94 (Col 29)CrossRefGoogle Scholar
  12. 12.
    Öberg K, Norheim I, Lind E, Alm G, Lundqvist G, Wide L, Jonsdottir B, Magnusson A, Wilander E (1986) Treatment of malignant carcinoid tumors with human leukocyte interferon: Long-term results. Cancer Treat Rep 70:1297–1304PubMedGoogle Scholar
  13. 13.
    Doberauer C, Niederle N, Kloke O, Kurschel E, Schmidt CG (1987) Zur Behandlung des metastasierten Karzinoids von Ileum und Caecum mit rekombinantem Interferon alpha-2b. Onkologie 10:340–344PubMedCrossRefGoogle Scholar
  14. 14.
    Maor MH, Maddux B, Osborne BM, Fuller LM, Sullivan JA, Nelson RS, Martin RG, Libsnitz HI, Velasquez WS, Bennett RW (1984) Stages IE and IIE non-Hodgkin’s lymphomas of the stomach. Comparison of treatment modalities. Cancer 54:2330–2337PubMedCrossRefGoogle Scholar
  15. 15.
    Schlag P, Schreml W, Herfarth CH, Abel U, Linder M, Queißer W, Trede M (1984) Wertigkeit einer adjuvanten Chemotherapie nach potentiell kurativer Operation des Magenkarzinoms. 5-Jahres-Ergebnisse einer kontrollierten randomisierten Untersuchung. In: Georgii A (Hrsg) Aspekte der klinischen Onkologie. Verhandlungen der Deutschen Krebsgesellschaft 5. Fischer Stuttgart New York, S 381–384Google Scholar
  16. 16.
    Coombes RC, Schein PS, Chilvers C, Palmer AJ, Wils J Beretta G, Amadori D, Cortes-Funes H, Villar Grimait A, McArdle C, Rauschecker H, Boven E, Magill G, Vassilopoulos P, Welvaart K, Pinto Ferreira E, Wiig J, Gisslebrecht C, Rougier P (1987) A controlled trial of FAM (5-FU, adriamycin, mitomycin-C) chemotherapy as adjuvant treatment for resected gastric carcinoma. Proc 4th Eur Conf Clin Oncol (ECCO), Madrid, 1–4 November, p 37 (abstract 142)Google Scholar
  17. 17.
    Higgins GA, Amadeo JH, McElhinney J, McCaughan JJ, Keehn RJ (1984) Efficacy of prolonged intermittent therapy with combined 5-fluorouracil and methyl-CCNU following resection for carcinoma of the large bowel. Cancer 53:1–8PubMedCrossRefGoogle Scholar
  18. 18.
    Gastrointestinal Tumor Study Group (1984) Adjuvant therapy of colong cancer — Results of a prospectively randomized trial. N Engl J Med 310:737–743CrossRefGoogle Scholar
  19. 19.
    Laurie J, Moertel C, Fleming T, Wieand H, Leigh J, Beart R, Cullinan S, Krook J (1986) Surgical adjuvant therapy of poor prognosis colorectal cancer with levamisole alone or combined levamisole and 5-fluorouracil (5-FU). A North Central Treatment Group and Mayo Clinic Study. Proc Am Soc Clin Oncol (ASCO) 5; 81 (abstract 316)Google Scholar
  20. 20.
    Schlag P, Herrmann R, Raeth U, Lehner B, Herfarth Ch, (1987) Neoadjuvant chemotherapy in esophageal cancer — Results of a phase II-trial. Proc 4th Eur Conf Clin Oncol (ECCO), Madrid, 1–4 November, p 31 (abstract 117)Google Scholar
  21. 21.
    Fritze D (1986) Behandlung des primären und des fortgeschrittenen Ösophaguskarzinoms durch Chemotherapie. In: Queißer W, Flechtner H (Hrsg) Gastrointestinale Tumoren. Fortschritte der Chemotherapie. Zuckschwerdt, München Bern Wien San Franzisco, S 47Google Scholar
  22. 22.
    Wilke H, Preusser P, Fink U, Klink M, Meyer J, Meyer H-J, Gunzer U, Schmoll HJ (1987) Preoperative „neoadjuvant“ chemotherapy with etoposide/adriamycin/Cisplatin (EAP) in local advanced gastric cancer. Proc 4th Eur Conf Clin Oncol (ECCO), Madrid, 1–4 November, p 32 (abstract 119)Google Scholar
  23. 23.
    Klein HO, Dias Wickramanayake P, Farrokh GR (1986) 5-fluorouracil (5-FU), adriamycin (ADM), and methotrexate (MTX) — a combination protocol (FAMTX) for treatment of metastasized stomach cancer. Proc Am Soc Clin Oncol (ASCO) 5:83Google Scholar
  24. 24.
    Wils J, Bleiberg H, Dalesio O, Blijham G, Mulder N, Planting A, Splinter T, Duez N (1986) An EORTC Gastrointestinal Group evaluation of the combination of sequential methotrexate and 5-fluorouracil, combined with adriamycin in advanced measurable gastric cancer. J Clin Oncol 4:1799–1803PubMedGoogle Scholar
  25. 25.
    Herrmann R, Fritze D, Queißer W, Flechtner H, Ho AD, Schlag P, König H (1984) Chemotherapie des Magenkarzinoms (Leserzuschrift). Dtsch Med Wochenschr 109:1704Google Scholar
  26. 26.
    Preusser P, Wilke H, Achterrath W, Fink U, Meyer J, Schmitz-Hübner U, Bünte H (1987) Advanced gastric carcinoma: A phase II study with etoposide (E), adriamycin (A) and split course Cisplatin (P) = EA. Proc Am Soc Clin Oncol (ASCO) 6:75 (abstract 292)Google Scholar
  27. 27.
    Eigene Daten, unpubliziertGoogle Scholar
  28. 28.
    Machover D, Goldschmidt E, Chollet P, Metzger G, Zittoun J, Marquet J, Vandenbulcke JM, Misset JL, Schwarzenberg L, Fourtillan JB, et al. (1986) Treatment of advanced colorectal and gastric adenocarcinomas with 5-flourouracil and high-dose folinic acid. J Clin Oncol 4:685–696PubMedGoogle Scholar
  29. 29.
    High-dose leucovorin and 5-flourouracil. A review of clinical studies in metastatic colorectal carcinoma and other cancers. Lederle International, Wayne, New Jersey, USA, 1987Google Scholar
  30. 30.
    Erlichman C, Fine S, Wong A, Elhakim T (1986) A comparison of 5-flourouracil (5FU) and folinic acid (FA) versus 5FU in metastatic colorectal carcinoma (MCC). Proc Am Soc Clin Oncol (ASCO) 5:82 (abstract 319)Google Scholar
  31. 31.
    Doroshow JH, Bertrand M, Multhauf P, Leong L, Goldberg D, Margolin K, Carr B, Akman S, Hill R (1987) Prospektive randomized trial comparing 5-FU versus (vs) 5-FU and high dose folinic acid (HDFA) for treatment of advanced colorectal cancer. Proc Am Soc Clin Oncol (ASCO) 6:96 (abstract 374)Google Scholar
  32. 32.
    Petrelli N, Herrera L, Stulc J, Burke P, Rustum Y, Mittelman A (1986) A phase III study of 5-fluorouracil (5-FU) versus 5-FU + methotrexate (MTX) versus 5-FU + high dose leucovorin (CF) in metastatic colorectal adenocarcinoma. Proc Am Soc Clin Oncol 5:78 (abstract 303)Google Scholar
  33. 33.
    Canobbio L, Nobile MT, Galligioni E, Vidili G, Fassio T, Lo Re G, Rubagotti A, Rosso R (1987) Randomized trial of 5-fluorouracil (5-FU) alone or combined with high dose folinic acid (FA) in advanced colorectal cancer patients (pts). Proc Am Soc Clin Oncol 6:97 (abstract 381)Google Scholar
  34. 34.
    Gallmeier WM, Bruntsch U (1987) Neue Zytostatika. Stand: 1986. Onkologie. 10:226–231PubMedCrossRefGoogle Scholar
  35. 35.
    Sternberg C, Kelsen D, Dukeman M, Leichman L, Heelan R (1985) Carboplatin: A new platinum analog in the treatment of epidermoid carcinoma of the esophagus. Cancer Treat Rep 69:1305–1307PubMedGoogle Scholar
  36. 36.
    Fiebig HH, Freiburg: unveröffentlichtGoogle Scholar
  37. 37.
    Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316:889–897PubMedCrossRefGoogle Scholar
  38. 38.
    Biberfeld P, Christensson B, Koprowski H, Mellstedt H, Philstedt P, Shetye J, Sundelius S, Sylven M, Wahren B (1987) Therapy of patients with metastasizing colo-rectal carcinoma with mouse monoclonal antibodies (MAb 17–1A). Proc Eur Conf Clin Oncol (ECCO), Madrid, 1–4 November, p 100 (abstract 374)Google Scholar

Copyright information

© J. F. Bergmann Verlag, München 1988

Authors and Affiliations

  • W. Queißer
    • 1
  1. 1.Onkologisches Zentrum, Klinikum Mannheim, Fakultät für klinische MedizinUniversität HeidelbergDeutschland

Personalised recommendations